Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer

Junghoon Shin, Jin-Haeng Chung, Se Hyun Kim, Kyu Sang Lee, Koung Jin Suh, Ji Yun Lee, Ji Won Kim, Jeong Ok Lee, Jin Won Kim, Yu Jung Kim, Keun Wook Lee, Jee Hyun Kim, Soo Mee Bang, Jong Seok Lee

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

Purpose Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression and its clinical implications. Materials and Methods We used immunohistochemistry to retrospectively evaluate the percentage of tumor cells with membranous PD-L1 staining (tumor proportion score) in paired tumor specimens obtained before and after platinum-based neoadjuvant chemotherapy (NACT) in 86 patients with NSCLC. We analyzed the correlation between the change in PD-L1 tumor proportion score and clinicopathologic characteristics, response to NACT, and survival. Results The PD-L1 tumor proportion score increased in a significant proportion of patients with NSCLC after platinum-based NACT (Wilcoxon signed-rank test, p=0.002). That pattern was consistent across clinically defined subgroups except for patients with partial response to NACT. Tumors from 26 patients (30.2%) were PD-L1!negative before NACT but PD-L1-pos-itive after NACT, whereas the reverse pattern occurred in six patients (7%) (McNemar’s test, p < 0.001). Increase in PD-L1 tumor proportion score was significantly associated with lack of response to NACT (Fisher exact test, p=0.015). There was a tendency, albeit not statistically significant, for patients with an increase in PD-L1 tumor proportion score to have shorter survival. Conclusion Tumor PD-L1 expression increased after platinum-based NACT in a significant proportion of patients with NSCLC. Increase in tumor PD-L1 expression may predict poor clinical outcome.

Original languageEnglish
Pages (from-to)1086-1097
Number of pages12
JournalCancer Research and Treatment
Volume51
Issue number3
DOIs
StatePublished - 1 Jul 2019

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
Drug Therapy
Neoplasms
Survival
Nonparametric Statistics
Immunohistochemistry
Staining and Labeling
Ligands

Keywords

  • Neoadjuvant therapy
  • Non-small cell lung carcinoma
  • PD-L1
  • Platinum
  • Prognosis

Cite this

Shin, Junghoon ; Chung, Jin-Haeng ; Kim, Se Hyun ; Lee, Kyu Sang ; Suh, Koung Jin ; Lee, Ji Yun ; Kim, Ji Won ; Lee, Jeong Ok ; Kim, Jin Won ; Kim, Yu Jung ; Lee, Keun Wook ; Kim, Jee Hyun ; Bang, Soo Mee ; Lee, Jong Seok. / Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer. In: Cancer Research and Treatment. 2019 ; Vol. 51, No. 3. pp. 1086-1097.
@article{a6638089e58b4823be22819d639c25f0,
title = "Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer",
abstract = "Purpose Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression and its clinical implications. Materials and Methods We used immunohistochemistry to retrospectively evaluate the percentage of tumor cells with membranous PD-L1 staining (tumor proportion score) in paired tumor specimens obtained before and after platinum-based neoadjuvant chemotherapy (NACT) in 86 patients with NSCLC. We analyzed the correlation between the change in PD-L1 tumor proportion score and clinicopathologic characteristics, response to NACT, and survival. Results The PD-L1 tumor proportion score increased in a significant proportion of patients with NSCLC after platinum-based NACT (Wilcoxon signed-rank test, p=0.002). That pattern was consistent across clinically defined subgroups except for patients with partial response to NACT. Tumors from 26 patients (30.2{\%}) were PD-L1!negative before NACT but PD-L1-pos-itive after NACT, whereas the reverse pattern occurred in six patients (7{\%}) (McNemar’s test, p < 0.001). Increase in PD-L1 tumor proportion score was significantly associated with lack of response to NACT (Fisher exact test, p=0.015). There was a tendency, albeit not statistically significant, for patients with an increase in PD-L1 tumor proportion score to have shorter survival. Conclusion Tumor PD-L1 expression increased after platinum-based NACT in a significant proportion of patients with NSCLC. Increase in tumor PD-L1 expression may predict poor clinical outcome.",
keywords = "Neoadjuvant therapy, Non-small cell lung carcinoma, PD-L1, Platinum, Prognosis",
author = "Junghoon Shin and Jin-Haeng Chung and Kim, {Se Hyun} and Lee, {Kyu Sang} and Suh, {Koung Jin} and Lee, {Ji Yun} and Kim, {Ji Won} and Lee, {Jeong Ok} and Kim, {Jin Won} and Kim, {Yu Jung} and Lee, {Keun Wook} and Kim, {Jee Hyun} and Bang, {Soo Mee} and Lee, {Jong Seok}",
year = "2019",
month = "7",
day = "1",
doi = "10.4143/crt.2018.537",
language = "English",
volume = "51",
pages = "1086--1097",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "3",

}

Shin, J, Chung, J-H, Kim, SH, Lee, KS, Suh, KJ, Lee, JY, Kim, JW, Lee, JO, Kim, JW, Kim, YJ, Lee, KW, Kim, JH, Bang, SM & Lee, JS 2019, 'Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer', Cancer Research and Treatment, vol. 51, no. 3, pp. 1086-1097. https://doi.org/10.4143/crt.2018.537

Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer. / Shin, Junghoon; Chung, Jin-Haeng; Kim, Se Hyun; Lee, Kyu Sang; Suh, Koung Jin; Lee, Ji Yun; Kim, Ji Won; Lee, Jeong Ok; Kim, Jin Won; Kim, Yu Jung; Lee, Keun Wook; Kim, Jee Hyun; Bang, Soo Mee; Lee, Jong Seok.

In: Cancer Research and Treatment, Vol. 51, No. 3, 01.07.2019, p. 1086-1097.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer

AU - Shin, Junghoon

AU - Chung, Jin-Haeng

AU - Kim, Se Hyun

AU - Lee, Kyu Sang

AU - Suh, Koung Jin

AU - Lee, Ji Yun

AU - Kim, Ji Won

AU - Lee, Jeong Ok

AU - Kim, Jin Won

AU - Kim, Yu Jung

AU - Lee, Keun Wook

AU - Kim, Jee Hyun

AU - Bang, Soo Mee

AU - Lee, Jong Seok

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Purpose Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression and its clinical implications. Materials and Methods We used immunohistochemistry to retrospectively evaluate the percentage of tumor cells with membranous PD-L1 staining (tumor proportion score) in paired tumor specimens obtained before and after platinum-based neoadjuvant chemotherapy (NACT) in 86 patients with NSCLC. We analyzed the correlation between the change in PD-L1 tumor proportion score and clinicopathologic characteristics, response to NACT, and survival. Results The PD-L1 tumor proportion score increased in a significant proportion of patients with NSCLC after platinum-based NACT (Wilcoxon signed-rank test, p=0.002). That pattern was consistent across clinically defined subgroups except for patients with partial response to NACT. Tumors from 26 patients (30.2%) were PD-L1!negative before NACT but PD-L1-pos-itive after NACT, whereas the reverse pattern occurred in six patients (7%) (McNemar’s test, p < 0.001). Increase in PD-L1 tumor proportion score was significantly associated with lack of response to NACT (Fisher exact test, p=0.015). There was a tendency, albeit not statistically significant, for patients with an increase in PD-L1 tumor proportion score to have shorter survival. Conclusion Tumor PD-L1 expression increased after platinum-based NACT in a significant proportion of patients with NSCLC. Increase in tumor PD-L1 expression may predict poor clinical outcome.

AB - Purpose Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression and its clinical implications. Materials and Methods We used immunohistochemistry to retrospectively evaluate the percentage of tumor cells with membranous PD-L1 staining (tumor proportion score) in paired tumor specimens obtained before and after platinum-based neoadjuvant chemotherapy (NACT) in 86 patients with NSCLC. We analyzed the correlation between the change in PD-L1 tumor proportion score and clinicopathologic characteristics, response to NACT, and survival. Results The PD-L1 tumor proportion score increased in a significant proportion of patients with NSCLC after platinum-based NACT (Wilcoxon signed-rank test, p=0.002). That pattern was consistent across clinically defined subgroups except for patients with partial response to NACT. Tumors from 26 patients (30.2%) were PD-L1!negative before NACT but PD-L1-pos-itive after NACT, whereas the reverse pattern occurred in six patients (7%) (McNemar’s test, p < 0.001). Increase in PD-L1 tumor proportion score was significantly associated with lack of response to NACT (Fisher exact test, p=0.015). There was a tendency, albeit not statistically significant, for patients with an increase in PD-L1 tumor proportion score to have shorter survival. Conclusion Tumor PD-L1 expression increased after platinum-based NACT in a significant proportion of patients with NSCLC. Increase in tumor PD-L1 expression may predict poor clinical outcome.

KW - Neoadjuvant therapy

KW - Non-small cell lung carcinoma

KW - PD-L1

KW - Platinum

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85068014171&partnerID=8YFLogxK

U2 - 10.4143/crt.2018.537

DO - 10.4143/crt.2018.537

M3 - Article

VL - 51

SP - 1086

EP - 1097

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 3

ER -